BR112022001185A2 - Method of eliciting an immune response by administering a population of polymerosomes having an associated antigen with a population of polymerosomes having an associated adjuvant, as well as compositions comprising the two populations of polymerosomes - Google Patents

Method of eliciting an immune response by administering a population of polymerosomes having an associated antigen with a population of polymerosomes having an associated adjuvant, as well as compositions comprising the two populations of polymerosomes

Info

Publication number
BR112022001185A2
BR112022001185A2 BR112022001185A BR112022001185A BR112022001185A2 BR 112022001185 A2 BR112022001185 A2 BR 112022001185A2 BR 112022001185 A BR112022001185 A BR 112022001185A BR 112022001185 A BR112022001185 A BR 112022001185A BR 112022001185 A2 BR112022001185 A2 BR 112022001185A2
Authority
BR
Brazil
Prior art keywords
polymerosomes
population
eliciting
populations
immune response
Prior art date
Application number
BR112022001185A
Other languages
Portuguese (pt)
Inventor
Kumar Khan Amit
Fabien Decaillot
Madhavan Nallani
Andrew Cornell Thomas
Original Assignee
Acm Biolabs Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acm Biolabs Pte Ltd filed Critical Acm Biolabs Pte Ltd
Publication of BR112022001185A2 publication Critical patent/BR112022001185A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

método de eliciamentode uma resposta imune administrando uma população depolimerossomos tendo um antígeno associado com uma população de pimerissomos tendo um adjuvante associado, bem como composição compreendendo as duas populações de polimerossomos. a presente invenção refere-se a um método de eliciar uma resposta imune em um indivíduo por administração de um antígeno e um adjuvante, em que o antígeno é associado com uma primeira população de polimerossomos, e em que o adjuvante é associado com uma segunda população de polimerossomos, e em que as duas populações de polimerossomos são administradas ao indivíduo. a presente invenção também se refere a composições, tais como, vacinas compreendendo as duas populações de polimerossomos da presente invenção, métodos de eliciar uma resposta imune ou métodos para tratamento, melhora, profilaxia ou diagnósticos de um câncer, doença autoimune ou infecciosa, compreendendo fornecer polimerossomos da presente invenção.method of eliciting an immune response by administering a population of polymerosomes having an associated antigen with a population of pimersomes having an associated adjuvant, as well as a composition comprising the two populations of polymerosomes. The present invention relates to a method of eliciting an immune response in an individual by administering an antigen and an adjuvant, wherein the antigen is associated with a first population of polymerosomes, and wherein the adjuvant is associated with a second population. of polymerosomes, and wherein the two populations of polymerosomes are administered to the individual. the present invention also relates to compositions, such as vaccines comprising the two populations of polymerosomes of the present invention, methods of eliciting an immune response or methods for treating, ameliorating, prophylaxis or diagnosis of a cancer, autoimmune or infectious disease, comprising providing polymerosomes of the present invention.

BR112022001185A 2019-08-01 2020-08-03 Method of eliciting an immune response by administering a population of polymerosomes having an associated antigen with a population of polymerosomes having an associated adjuvant, as well as compositions comprising the two populations of polymerosomes BR112022001185A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19189549 2019-08-01
EP20171327 2020-04-24
PCT/EP2020/071809 WO2021019102A2 (en) 2019-08-01 2020-08-03 A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersomes

Publications (1)

Publication Number Publication Date
BR112022001185A2 true BR112022001185A2 (en) 2022-03-15

Family

ID=72148072

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022001185A BR112022001185A2 (en) 2019-08-01 2020-08-03 Method of eliciting an immune response by administering a population of polymerosomes having an associated antigen with a population of polymerosomes having an associated adjuvant, as well as compositions comprising the two populations of polymerosomes

Country Status (8)

Country Link
US (1) US20220273792A1 (en)
EP (1) EP4007597A2 (en)
JP (1) JP2022543038A (en)
CN (1) CN114502191A (en)
AU (1) AU2020322107A1 (en)
BR (1) BR112022001185A2 (en)
CA (1) CA3143533A1 (en)
WO (1) WO2021019102A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102657261B1 (en) * 2020-04-03 2024-04-15 조선대학교산학협력단 Recombinant COVID-19 spike proteins for diagnosis of COVID-19 and use thereof
AU2021260857A1 (en) * 2020-04-24 2022-11-03 Acm Biolabs Pte Ltd Vaccine against human-pathogenic coronaviruses
WO2021226533A1 (en) 2020-05-08 2021-11-11 Academia Sinica Chimeric influenza vaccines
AU2021396659A1 (en) * 2020-12-11 2023-05-04 Acm Biolabs Pte Ltd Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant
CA3204785A1 (en) * 2021-02-02 2022-08-11 Madhavan Nallani Sole use of polymersome associated adjuvant for stimulating an immune response
WO2022171182A1 (en) * 2021-02-10 2022-08-18 斯微(上海)生物科技股份有限公司 Vaccine reagent for treating or preventing coronavirus mutant strain
WO2022197840A1 (en) * 2021-03-16 2022-09-22 The Wistar Institute Adenovirus sars-cov-2 vaccine
WO2022212505A1 (en) * 2021-03-30 2022-10-06 Arizona Board Of Regents On Behalf Of Arizona State University Optimal production of sars-cov-2 virus-like particles (vlps) produced in mammalian cells
CA3197160A1 (en) * 2021-04-12 2022-10-20 Academia Sinica Messenger rna vaccines against wide spectrum of coronavirus variants
AU2022257113A1 (en) * 2021-04-12 2023-02-16 Academia Sinica Improved coronavirus vaccine
CN115337404A (en) * 2021-05-12 2022-11-15 中国医学科学院基础医学研究所 Application of cell microparticles in treatment of respiratory viral pneumonia
US20230043887A1 (en) * 2021-05-24 2023-02-09 Venkataramanan Soundararajan Compositions and methods related to surge-associated sars-cov-2 mutants
WO2023004415A2 (en) * 2021-07-22 2023-01-26 University Of Miami Sars-cov-2 vaccine using bacterial spores expressing antigenic fragments
IT202100023816A1 (en) * 2021-09-16 2023-03-16 Takis S R L Antibody against SARS-CoV-2 and its uses in the medical field.
TW202334429A (en) 2021-10-01 2023-09-01 中央研究院 Antibody specific to spike protein of sars-cov-2 and uses thereof
WO2023060220A1 (en) * 2021-10-07 2023-04-13 BioVaxys Inc. Methods of immunization against coronavirus
CN114470186B (en) * 2022-02-17 2023-10-20 唐颐控股(深圳)有限公司 Preparation method of inhalable nanometer new crown vaccine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
WO2014057128A2 (en) 2012-10-11 2014-04-17 Vin-De-Bona Trading Company Pte Ltd Method of painting microvesicles
EP2281033B1 (en) 2008-04-17 2014-10-15 Vin de Bona Trading Co Pte Post release modification of viral envelopes
US8323696B2 (en) 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
WO2010123462A1 (en) 2009-04-20 2010-10-28 Agency For Science, Technology And Research Vesicular system and uses thereof
EP2601262A4 (en) 2010-08-05 2014-01-22 Agency Science Tech & Res A multicompartmentalized vesicular structure and a method for forming the same
US20150044242A1 (en) 2012-03-12 2015-02-12 Advanced Bioadjuvants Llc Adjuvant and Vaccine Compositions
US9962438B2 (en) 2012-11-19 2018-05-08 Agency For Science, Technology And Research Method for eliciting an immune response to an immunogen
EP2898894A1 (en) 2014-01-27 2015-07-29 LTS LOHMANN Therapie-Systeme AG Nano-in-micro particles for intradermal delivery
WO2016055611A1 (en) * 2014-10-09 2016-04-14 Universität Basel Self-assembled nanostructures and methods of use thereof
CA2979556C (en) 2015-03-24 2023-07-18 VaxLiant, LLC Adjuvant compositions and related methods

Also Published As

Publication number Publication date
CN114502191A (en) 2022-05-13
AU2020322107A1 (en) 2022-02-03
WO2021019102A3 (en) 2021-03-11
JP2022543038A (en) 2022-10-07
US20220273792A1 (en) 2022-09-01
CA3143533A1 (en) 2021-02-04
EP4007597A2 (en) 2022-06-08
WO2021019102A2 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
BR112022001185A2 (en) Method of eliciting an immune response by administering a population of polymerosomes having an associated antigen with a population of polymerosomes having an associated adjuvant, as well as compositions comprising the two populations of polymerosomes
BR112017017949A2 (en) initiation-booster regimens involving administration of at least one mrna construct
CO2017011245A2 (en) Group B streptococcus protein-polysaccharide conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates and their uses
BR112018007525A2 (en) porcine circovirus immunogenic compositions and methods of producing and using them
MX2021015775A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof.
BR112017008042A2 (en) methods and compositions for dosage in adoptive cell therapy
EP3616716A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BRPI0912411B8 (en) use of a human interleukin-2 mutein (hil-2 mutein) and pharmaceutical composition for the treatment and/or prophylaxis of an autoimmune disease
BR112016028816A2 (en) immunogenic combination, method for obtaining a specific immune response, use of an immunogenic combination, vaccination regimen for prevention, reduction or treatment of respiratory syncytial virus infection, and, kit.
BR112018001572A2 (en) method for inducing an immune response, antigen, adenovirus, use of antigen and adenovirus, and polynucleotide.
BR112019014397A2 (en) COMPOSITIONS OF NEISSERIA MENINGITIDIS AND METHODS OF THE SAME
BR112017020780A2 (en) Glutaminase inhibitor administration methods
BR112013032251A2 (en) stable composition of the inactivated chikungunya virus strain vaccine with one or more mutations; method for inducing a protective immune response in human individuals against chikungunya virus infections; use of chikungunya virus isolates; combined vaccine composition
BR112017023867A2 (en) methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers
BR112018017031A2 (en) il-6 antagonist formulations and uses thereof
BR112018075440A2 (en) compositions and methods for preventing and treating Zika virus infection
BR112015012711A2 (en) method of production of a mycoplasma vaccine
BR112017002440A2 (en) mutant porcine epizootic diarrhea virus for use in a vaccine
BR112012028893A2 (en) immunostimulatory and vaccine compositions
BR112018068342A2 (en) live attenuated zika virus vaccine
BR112021019859A2 (en) Porcine circovirus type 3 (pcv3) vaccines and production and uses
BR112018015893A2 (en) cancer vaccines and treatment methods using the same
BR112018008697A2 (en) method and kit for vaccination against an autoantigen, use of a kit, and vaccine for use in vaccination.
BR112012026007A2 (en) method and compositions for inhibition of treg cells as well as use of allogeneic th1 cells and a source of antigens
BR112022020298A2 (en) VACCINES, ADJUVANTS AND METHODS TO GENERATE AN IMMUNE RESPONSE